MEMORANDUM FOR ASSISTANT SECRETARY OF THE ARMY (M&RA)
ASSISTANT SECRETARY OF THE NAVY (M&RA)
ASSISTANT SECRETARY OF THE AIR FORCE (SAF/MR)
DIRECTOR, JOINT STAFF

SUBJECT: Operation Iraqi Freedom Depleted Uranium Medical Management

The Department of Defense (DoD) policy for medical management of Operation Iraqi Freedom (OIF) personnel with Depleted Uranium (DU) exposures (Health Affairs (HA) Policy 03-12/www.ha.osd.mil/policies/2003/03-012.pdf) was implemented in June 2003. In order to assess the impact of the policy and to more closely monitor the numbers of personnel with documented exposures to DU, I am requesting the Services report their DU Urine Bioassay results in 30 days from the date of this memo (for the period June 2003 – March 31, 2004), to the Deployment Health Support Directorate. Report semiannual and cumulative totals.

The reports will include the number of Level I and Level II DU exposed personnel, source of exposed personnel, number of Level I and Level II exposures assessed qualitatively (i.e., through questionnaires and interviews), percentage of those Level I and Level II exposures evaluated with a urine uranium test, status of urine DU bioassay evaluations, status of reporting results to patients, and number of referrals to the Baltimore Veterans Affairs Medical Center's DU Follow-up Program. In addition, I am requesting additional detail on Level I exposures with fragment-type injuries. Data tables are provided in Attachment 1 to aid in collecting and reporting this information.

In implementing this policy, we found some areas needing clarification. The following guidance supplements HA Policy 03-12 in identification of exposed personnel, exposure assessment, bioassay procedures, surveillance and tracking, and case management:

- Depleted Uranium-Exposed Personnel Identification. Services should not rely entirely upon answers on the DD Form 2796, “Post Deployment Health Assessment (PDHA),” for this purpose. Locating units involved in operations or incidents resulting in possible DU exposures may identify others requiring evaluation.
• Depleted Uranium Exposure Assessment Upon referral for determination of the DU exposure level, healthcare providers will evaluate personnel for possible DU exposure based on in-theater experiences. Complete the DoD DU Questionnaire and Health Survey Forms (currently DD Form 2872 Test and DD Form 2872-1 Test), to be overprinted on a single SF-600 in the near future, for each individual assessed. These forms are available from the DoD Deployment Health Clinical Center (DHCC) website, www.pdhealth.mil, or DHCC can assist directly (contact information provided at Attachment 3). For all personnel, regardless of identification method, use the DU Questionnaire and other available supporting information, such as incident reports or descriptions of exposure conditions, to assign patients to one of three DU exposure categories: Level I, II, or III as described in Health Affairs Policy 03-012.

• Depleted Uranium Bioassay Procedures. To ensure that urine specimen containers are free of natural uranium contamination, contact testing laboratories for the type of container to use. Testing for DU within the 180-day window increases the ability to detect lower-level exposures. Nevertheless, urine excretion of uranium, in general, continues after the 180 days; therefore, collect samples for the initial evaluation of DU exposure even when the earliest possible testing opportunity presents after the 180-day period. Laboratories performing the urine bioassays should store a 250-ml aliquot of the urine tested indefinitely. See the "Protocol for DU Urine Validation Testing and Referrals to the Baltimore Veterans Affairs (VA) Follow-up Program" (Attachment 2) for interpretation of results. Coordinate referrals to the VA through the DoD Deployment Health Clinical Center, located at the Walter Reed Army Medical Center.

• Depleted Uranium Exposure Surveillance and Tracking. Collect and maintain exposure-related information in sufficient detail to characterize the exposure for use in follow-on investigations, evaluations, and health risk assessments. Compare that information with servicemembers identified with DU exposures and reports of possible contact with DU-contaminated equipment to ensure appropriate evaluations occur.

• Archiving and DU Case Management. The DHCC will serve as the central archive for all DoD patient information related to DU exposure, testing, and follow-up for active duty and reserve personnel. Forward lab results, assessment questionnaires, referrals, and narrative summaries from follow-up care to DHCC for archiving. Service labs and the Baltimore VA will forward.
• all DU exposure assessment and testing results to DHCC for archiving upon completion of health services

• More detailed supplemental information and clinical guidance on these topics and others is now available on the DHCC website, www.health.mil

My point of contact is COL Sulka, who can be reached at (703) 681-3279 x131, Daniel.Sulka@deploymenthealth.osd.mil.

William Winkenwerder, Jr., MD

Attachments:
As stated
ATTACHMENT 1
### OIF DU EXPOSURE SEMI-ANNUAL PROGRESS REPORT

DU/Fragment Exposure Assessment, Testing, and Results Information

**Reporting Period**

<table>
<thead>
<tr>
<th>Service</th>
<th>Report Date</th>
<th>POC (Name/Phone Number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure Level</td>
<td>No. Personnel Identified</td>
<td>Self</td>
</tr>
<tr>
<td>I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total this report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cumulative Totals</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Exposure Level I Fragment Information**

<table>
<thead>
<tr>
<th>Fragment Type</th>
<th>Number of Patients with Fragments</th>
<th>Urine Bioassay Results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial Positive</td>
<td>Confirmed Positive</td>
</tr>
<tr>
<td>DU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other metal; specify</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other metal; specify</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other metal; specify</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total this report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cumulative Totals</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**

1. Positive response to Question 37a or 37b on the DU Exposure Questionnaire--(DoD 2872 Test/SF 600 overprint)
2. Urinalysis >= 50ng Uranium per gram creatinine
3. Urinalysis >= 50ng Uranium per gram creatinine, initial and follow up specimens
4. Urinalysis < 50ng Uranium per gram creatinine
5. If fragment types are known, identify them in the space provided
6. Cumulative totals will reflect total of this report as well as those on any previous progress reports

* All three cells with this symbol should reflect the same value
ATTACHMENT 2
Protocol for Urine DU Bioassay Validation Testing and Referrals to the Baltimore VA Follow-up Program

24-Hour Urine Samples

1. If urine [total U] is < 50 ng/g creatinine (cre) and isotopic analysis indicates presence of DU with or without evidence of embedded fragments, then repeat urine analysis in 6 months.

2. If urine [total U] is < 50 ng/g cre and isotopic analysis does not indicate presence of DU, then no follow-up is necessary.

3. If urine [total U] is ≥ 50 ng/g cre or isotopic analysis indicates the sample contains DU at 10% or more, then perform urine uranium analysis on a repeat 24-hr urine sample for confirmation.
   a. If second urine [total U] is still ≥ 50 ng/g cre or isotopic analysis indicates presence of 10% or more DU, then complete a radiological skeletal survey to look for evidence of embedded fragments.
   b. If there is no evidence of embedded fragments on the radiological skeletal survey, then repeat urine DU analysis in 6 months. If still positive after 6 months, the primary care manager first consults with DHCC and, if appropriate, contacts the Baltimore VA for follow-up care.

4. If a servicemember has embedded fragments or fragment-type injuries and a urine [total U] ≥ 50 ng/g cre and isotopic analysis indicates the presence of DU at 10% or more, primary care manager refers patient to the Baltimore VA In-Patient DU Follow-up Program after consulting DHCC.

Note: all creatinine values used in the calculations to normalize results are urine creatinine concentrations.

Spot Urine Samples

Follow all spot samples with [Total U] ≥ 25ng/g cre with a 24-hour urine test and interpret as above. No follow-up is required for samples with results with [Total U] < 25 ng/g cre.
ATTACHMENT 3
Consultation and Referral Points of Contact

DHCC Archiving and Consultation Information

The DoD Deployment Health Clinical Center (DHCC) medical staff is available to discuss DU evaluation and management: archiving: case management procedures, including referral to the Baltimore VA; and to provide forms and documents. Forward all required documentation to DHCC, either in hard or electronic copy to:

DoD Deployment Health Clinical Center
Walter Reed Army Medical Center
6900 Georgia Avenue, NW
Bldg 2, Rm 3G04
Washington, DC 20307-5001

Clinician Helpline: 1-866-559-1627
Toll-free from Europe: 00800-8666-8666
Phone: 202-782-6563
DSN: 662-6563
Fax: 202-782-3539
Email: pdhealth@na.amedd.army.mil
Website: www.pdhealth.mil

Baltimore VA DU Medical Follow-up Consultation and Referral Information

The VA medical staff is available to discuss the management of any patient’s case with a clinician to provide guidance for follow-up decisions and discussions with the patient. Contact Information is:

Depleted Uranium Follow-up Program
Baltimore VA Medical Center (11DU)
10 N. Greene Street
Baltimore, MD 21201
1-800-815-7533